XTNT Stock Analysis

Xtant Medical Holdings Inc
HEALTHCARE MEDICAL DEVICES

Back to Winners View Yahoo Finance Chart Buy on the Dip
Strong Caution Mixed Weak Unavailable
StockValueFinder Grade
D
45.32 / 100
Below Average
Confidence: Very High (96.0%) Coverage: 96.0%
Business Quality 28.9
Financial Strength 62.3
Earnings & Growth 38.3
Valuation 82.5
Market Strength 10.0
The grade combines Business Quality, Financial Strength, Earnings & Growth, Valuation, and Market Strength. Rating and Trend remain separate signals.
Rating AVOID
Avoid
The screening rules are warning against this setup.
Rating is the simple decision label from the screening rules.
Trend SELL / AVOID TREND
Weak Trend
The current trend is unfavorable.
Trend shows whether price action is helping or hurting the setup.
P/E Ratio 7.86
Value-Friendly
Below 15 is a classic value screen, but not proof of a bargain.
P/E shows how much investors pay for each dollar of earnings.
ROIC 6.24%
Borderline
Below 10% is usable but not especially strong.
ROIC measures how efficiently capital turns into profit.
Debt Payback 1.08 yrs
Strong
Under 3 years is generally a strong balance-sheet sign.
Debt payback estimates how quickly debt could be covered.
Interest Coverage 1.98x
Weak
Low coverage can make debt more risky.
Interest coverage shows how easily earnings cover interest costs.
Price $0.28
Market Price
Price alone is not a buy or sell signal.
Price should be judged with valuation, quality, and trend.
Last updated: 2026-10-24 01:12:32

Performance Overview

Trailing adjusted-close returns as of 2026-08-04. Benchmark is SPY.

YTD Return

XTNT -44.41%
SPY +13.71%

1-Year Return

XTNT -21.12%
SPY +23.56%

3-Year Return

XTNT -57.69%
SPY +79.19%

5-Year Return

XTNT -67.23%
SPY +88.04%

Returns are calculated from adjusted close prices and may differ from broker or research-site totals depending on data source, dividend handling, benchmark choice, and latest available trading date.

Legacy Screening Checks

This page uses cached SQL data from the latest StockValueFinder scan, so it loads fast without hitting Alpha Vantage on every page view.

33%
EPS Strength
FAIL

Looks for positive and improving earnings per share.

ROIC 10%+
FAIL

Looks for strong return on invested capital.

Interest Coverage 6+
FAIL

Checks whether operating income comfortably covers interest expense.

Debt Payback ≤ 3 Years
PASS

Checks whether free cash flow could pay down long-term debt quickly.

P/E 15 or Less
PASS

Checks whether valuation is reasonable under the current rule set.

Moving Average Trend
SELL / AVOID TREND

Uses 20-day, 50-day, and 200-day moving averages for entry timing context.

A high StockValueFinder score is a research signal, not a guarantee. Strong companies can still fall during recessions, sector downturns, valuation resets, or company-specific events. Always review the business, risks, SEC filings, valuation, and your personal investment goals before buying.

Cached Technical Data

Moving average values from the latest stored scan.

20-Day MA0.32
50-Day MA0.34
200-Day MA0.47
MA Score0

Latest Published Stock Research

Research generated: October 23, 2026

XTNT Stock Analysis: Why Xtant Medical Holdings Inc Scored 33% in Stock Value Finder

Xtant Medical Holdings Inc (XTNT): A Comprehensive Financial Research Review

Welcome to this educational stock research review provided by StockValueFinder.com. In this article, we will perform a deep dive into Xtant Medical Holdings Inc (XTNT), a company operating within the Healthcare sector and specifically the Medical Devices industry. The purpose of this review is not to provide a buy or sell recommendation, but to use XTNT as a case study to teach investors how to evaluate a company using a disciplined, number-driven approach.

By analyzing specific metrics—such as Return on Invested Capital (ROIC), Price-to-Earnings (P/E) ratios, and debt payback periods—investors can move away from emotional decision-making and toward a systematic process of financial screening. In this review, we will examine why Xtant Medical Holdings Inc received its current score and how you can apply these same tests to any other ticker in your portfolio.

Why the StockValueFinder Score Matters

The StockValueFinder system assigns a percentage score to stocks based on a battery of financial health and valuation tests. For Xtant Medical Holdings Inc (XTNT), the current score is 33%, and the resulting rating is AVOID.

A score of 33% indicates that the company failed the majority of the system's strict quality and safety screens. In a disciplined investment framework, a high score (typically 70% or above) suggests that a company possesses a combination of strong earnings growth, efficient capital usage, manageable debt, and an attractive valuation. A low score, such as 33%, serves as a red flag, suggesting that while some individual metrics may look positive, the overall financial profile does not meet the criteria for a high-quality investment.

Understanding this score is the first step in "filtering." Instead of spending hours researching every company in the medical device industry, an investor can use these scores to quickly identify which companies merit further study and which ones possess too many systemic risks.

EPS Strength and Consistency

Earnings Per Share (EPS) is a primary indicator of a company's profitability. It represents the portion of a company's profit allocated to each outstanding share of common stock. For investors, the consistency of EPS is often more important than a single year of high growth; consistent earnings suggest a stable business model and predictable cash flows.

In the case of Xtant Medical Holdings Inc, the EPS test result is: **Did not pass**.

While the specific historical EPS figures were not supplied for this review, the system recorded a failure for this metric. When a stock fails the EPS test, it typically means the company has experienced inconsistent earnings, negative earnings (losses), or a lack of growth that meets the system's minimum threshold for "strength."

**Educational Example:** Imagine Company A has an EPS of $1.00, $1.10, and $1.20 over three years. This shows steady growth and would likely pass a consistency test. Now imagine Company B has an EPS of $2.00, then -$0.50, then $0.10. Even though Company B had one very high year, the volatility makes it risky. The system marks these inconsistencies as a failure because unpredictability increases the risk of capital loss.

ROIC and Capital Efficiency

Return on Invested Capital (ROIC) is one of the most critical metrics for determining if a company is actually creating value. ROIC measures how efficiently a company uses its money (both debt and equity) to generate profit.

Xtant Medical Holdings Inc has a reported **ROIC of 6.24%**.

StockValueFinder generally prefers an ROIC of 10% or higher. A 10% threshold is often used because it typically exceeds the cost of capital; if a company earns 10% on its investments but it costs them 8% to borrow that money, they are creating value. If the ROIC is too low, the company may be destroying value by investing in projects that don't provide a sufficient return.

Because 6.24% is below the 10% benchmark, XTNT **did not pass** the ROIC test.

**Educational Example:** Consider two companies in the medical device space. Company X has an ROIC of 15%, while Company Y has an ROIC of 4%. Company X is significantly more efficient; for every dollar invested in the business, it generates 15 cents of profit. Company Y only generates 4 cents. Over a decade, the compounding effect of a 15% ROIC creates vastly more shareholder wealth than a 4% ROIC.

Interest Coverage and Financial Safety

Interest coverage is a solvency ratio that describes how easily a company can pay interest on its outstanding debt. It is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expenses.

For Xtant Medical Holdings Inc, the interest coverage test result is: **Did not pass**.

StockValueFinder prefers an interest coverage ratio of 6 or higher. A ratio of 6 means the company earns six times more than it needs to cover its interest payments, providing a significant "cushion" if earnings happen to drop. When a company fails this test, it suggests that a larger portion of its operating income is being consumed by debt costs, leaving the company vulnerable to economic downturns or rising interest rates.

**Educational Example:** If a company has $600,000 in earnings and $100,000 in annual interest payments, its coverage is 6x. This is considered healthy. However, if a company has $200,000 in earnings and $100,000 in interest payments, its coverage is only 2x. If earnings drop by just 20%, that company is suddenly in a precarious position where it may struggle to service its debt.

Debt Payback and Balance Sheet Discipline

While interest coverage looks at the ability to pay *interest*, the debt payback test looks at the ability to pay off the *entire principal* of the debt using annual cash flows. This is a measure of balance sheet discipline.

Xtant Medical Holdings Inc has a **debt payback period of 1.08 years**.

StockValueFinder prefers a debt payback period of 3 years or less. Because 1.08 years is well under the 3-year limit, XTNT **passed** this test. A short payback period is a positive sign; it indicates that the company is not overburdened by long-term debt relative to its current cash-generating ability.

**Educational Example:** If Company A has $1 million in debt and generates $500,000 in free cash flow per year, its payback period is 2 years. If Company B has $1 million in debt but only generates $100,000 in cash flow, its payback period is 10 years. Company A is in a much stronger position to clear its liabilities and reduce financial risk.

P/E Ratio and Valuation Discipline

The Price-to-Earnings (P/E) ratio tells us how much the market is willing to pay for every $1 of earnings. It is a primary tool for valuation discipline, helping investors avoid overpaying for a stock.

Xtant Medical Holdings Inc has a **P/E ratio of 7.86**.

StockValueFinder prefers a P/E of 15 or lower for valuation discipline. A lower P/E often suggests that a stock is "cheap" or undervalued relative to its earnings. Because 7.86 is well below 15, XTNT **passed** the P/E valuation test.

However, it is important to remember that a low P/E is not always a positive. Sometimes a P/E is low because the market expects the company's earnings to decline in the future. Valuation must always be balanced with quality (ROIC and EPS).

**Educational Example:** If a high-growth tech stock has a P/E of 40, you are paying $40 for every $1 of profit. If a stable medical company has a P/E of 8, you are paying only $8 for every $1 of profit. Assuming the business quality is sound, the P/E of 8 is more value-oriented and provides a larger margin of safety.

Moving Average Trend and Entry Timing

Fundamental analysis (P/E, ROIC, Debt) tells us *what* to buy, but technical analysis (Trends) helps us decide *when* to buy. StockValueFinder uses moving averages to determine if a stock is in an uptrend or a downtrend.

For XTNT, the moving average signal is **SELL / AVOID TREND**. Furthermore, the entry signal is listed as **N/A**.

A "Sell/Avoid" trend means the stock price is currently trading below its key moving averages, indicating downward momentum. In a disciplined system, buying a stock in a downtrend is often avoided, even if the valuation is low, because the price could continue to fall. The "N/A" for entry signals, limit buy ideas, and pullback zones indicates that the system has not identified a safe or attractive technical window to enter a position.

It is crucial to understand that a trend signal is used for timing discipline; it is not a guarantee that the stock *must* rise or fall, but rather a reflection of current market sentiment.

Overall Financial Strengths and Weaknesses

To summarize the findings for Xtant Medical Holdings Inc (XTNT), we can categorize the results into strengths and weaknesses:

**Strengths:** * **Valuation:** With a P/E of 7.86, the stock is priced attractively relative to its earnings. * **Debt Principal:** A debt payback period of 1.08 years suggests the company can clear its principal debt quickly.

**Weaknesses:** * **Capital Efficiency:** An ROIC of 6.24% is below the 10% benchmark, indicating suboptimal use of capital. * **Earnings Stability:** The failure of the EPS test suggests a lack of consistent profitability. * **Solvency Cushion:** The failure of the interest coverage test indicates a tighter margin for paying interest expenses. * **Market Momentum:** The "SELL / AVOID TREND" signal suggests the stock is currently losing value in the market.

Risks and Limitations

Investing in small-cap medical device companies carries inherent risks. When a company has a low StockValueFinder score (33%), the primary risk is "value trapping." A value trap occurs when a stock looks cheap (low P/E) but continues to drop because the underlying business quality (ROIC, EPS) is deteriorating.

For XTNT, the combination of a failing ROIC test and a failing interest coverage test suggests that while the stock is "cheap" on paper, the business is not operating with the efficiency or safety required to be considered a high-quality investment. Additionally, the lack of a positive moving average trend increases the risk of further price depreciation.

Educational Conclusion

Xtant Medical Holdings Inc (XTNT) serves as an excellent example of why investors must look beyond a single metric. If an investor looked only at the P/E ratio (7.86) or the Debt Payback (1.08 years), they might conclude the stock is a bargain. However, by applying a full screen, we see that the company struggles with capital efficiency (ROIC) and interest coverage.

The StockValueFinder rating of AVOID and the score of 33% are the results of this holistic approach. By requiring a stock to pass tests for growth, efficiency, safety, and valuation simultaneously, investors can filter out companies that may look cheap but lack the fundamental strength to support long-term growth.

This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security.


Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings

Research Attribution
Omar Gemani

Specializing in global financial markets, macroeconomic trends, and equity valuation, Omar Gemani brings a disciplined, research-driven perspective to investment analysis. His editorial approach emphasizes company fundamentals, earnings sustainability, financial strength, and long-term growth potential. Combining fundamental analysis with broader economic indicators, Omar evaluates investment opportunities while highlighting market uncertainty, valuation risks, and the importance of capital preservation.

30-Day Trendline Analysis

Optional intraday chart with rising support, falling resistance, and multi-timeframe views.

Load detailed price structure only when needed. Downloads roughly 30 days of 5-minute candles, identifies swing points, then calculates validated support and resistance lines.
Scroll to Top